SCHEMBL101659

SCHEMBL101659

[CH2]CCC(C)CCCCCCCCCCCCCCCC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE2 Q9BYF1 1/20 0.52
OPRM1 P35372 1/20 0.44
LMNA P02545 2/20 0.42
SPHK1 Q9NYA1 1/20 0.41
PRKD3 O94806 1/20 0.41
PRKCG P05129 1/20 0.41
PRKCB P05771 1/20 0.41
PRKCA P17252 1/20 0.41
PRKCH P24723 1/20 0.41
PRKCI P41743 1/20 0.41
PRKCE Q02156 1/20 0.41
PRKCQ Q04759 1/20 0.41
PRKCZ Q05513 1/20 0.41
PRKCD Q05655 1/20 0.41
PRKD1 Q15139 1/20 0.41
DNM1 Q05193 2/20 0.40
TSHR P16473 1/20 0.40
THRB P10828 1/20 0.40
ADH1B P00325 1/20 0.39
ADH1C P00326 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11289246 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL201848 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL102916 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL199151 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL102766 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL199182 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL5090198 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL99895 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL102106 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3
SCHEMBL201353 1.00 ACE2 (0.52) ACE2OPRM1LMNASPHK1PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024018762-A1 PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE 国立大学法人北海道大学 2024-01-25 WO disclosed
WO-2024018761-A1 NEUTRAL LIPID AND LIPID NANOPARTICLE 国立大学法人北海道大学 2024-01-25 WO disclosed
CN-103068786-B Cosmetic preparation COGNIS IP MANAGEMENT GMBH (DE) 2016-01-20 CN disclosed
US-8940943-B2 Cosmetic preparations COGNIS IP MANAGEMENT GMBH (DE) 2015-01-27 US disclosed
US-8481736-B2 Liquid crystalline rylene tetracarboxylic acid derivatives and use thereof BASF SE (DE) 2013-07-09 US disclosed
EP-2601166-A1 COSMETIC PREPARATIONS Cognis IP Management GmbH (DE) 2013-06-12 EP disclosed
US-20130131188-A1 Cosmetic Preparations COGNIS IP MANAGEMENT GMBH (DE) 2013-05-23 US disclosed
CN-103068786-A Cosmetic preparation COGNIS IP MAN GMBH 2013-04-24 CN disclosed
EP-2426101-A1 Cosmetic preparations Cognis IP Management GmbH (DE) 2012-03-07 EP disclosed
WO-2012016642-A1 COSMETIC PREPARATIONS COGNIS IP MANAGEMENT GMBH (DE) 2012-02-09 WO disclosed
US-8088922-B2 Dibenzorylenetetracarboximides as infrared absorbers BASF AKTIENGESELLSCHAFT (DE) 2012-01-03 US disclosed
WO-2011138743-A1 USE OF PYROMELLITIC DIIMIDES IN ORGANIC ELECTRONICS AND ORGANIC PHOTOVOLTAICS BASF SE (DE) 2011-11-10 WO disclosed
US-20110042651-A1 LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF BASF SE (DE) 2011-02-24 US disclosed
WO-2010112452-A1 OLIGOCONDENSED PERYLENE BISIMIDES BASF SE (DE) 2010-10-07 WO disclosed
US-20100048904-A1 DIBENZORYLENETETRACARBOXIMIDES AS INFRARED ABSORBERS BASF AKTIENGESELLSCHAFT (DE) 2010-02-25 US disclosed
EP-0421441-B1 Pantothenic acid derivatives FUJIREBIO KK (JP) 1995-01-25 EP disclosed
US-5120738-A Cardiovascular disorders FUJIREBIO INC. (JP) 1992-06-09 US disclosed
EP-0421441-A2 Pantothenic acid derivatives FUJIREBIO INC. (JP) 1991-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048904-A1 DIBENZORYLENETETRACARBOXIMIDES AS INFRARED ABSORBERS TDO2, C9, CYP3A43 ACE2 1441/4885OPRM1 1941/4885LMNA 1646/4885
US-20110042651-A1 LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF TPR, ROR1, CA3 ACE2 3046/4885OPRM1 4561/4885LMNA 2934/4885
US-20130131188-A1 Cosmetic Preparations CYP1B1, CBR1, ACOX3 ACE2 3825/4885OPRM1 745/4885LMNA 1943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.